Abiomed, Inc. (NASDAQ: ABMD) today announced its participation in the Advanced Medical Technology Association (AdvaMed) "Profiles in Progress You Can See" events on Capitol Hill. This educational awareness program was created to improve understanding about the value of medical technology. Abiomed's Ventricular Assist Devices (VADs), which provide circulatory support for patients in acute heart failure, were among the advanced technologies highlighted during the Capitol Hill outreach and reception events. AdvaMed is the world's largest association representing manufacturers of medical devices, diagnostic products and medical information systems.
"The AdvaMed Capitol Hill events featured patients who have benefited from technological innovations, such as Abiomed's heart recovery devices. We continue strive to increase awareness for the use of VADs to recover native heart function following acute failure. We are encouraged by the awareness these events generated to continue to grow the medical device industry as a whole," said Michael R. Minogue, Chairman, CEO and President of Abiomed.
The events included a photographic exhibit of 25 patients whose lives were positively affected by medical devices or diagnostics. Abiomed's technology has benefited patients around the world and was highlighted by a viral myocarditis patient who recovered the native function of his heart following bi-ventricular circulatory support with an Abiomed VAD. The photo exhibit also included Senator Mike Crapo (R-ID), Olympic gold medalist Bonnie Blair, NBA veteran Fred Hoiberg, former Senator and Presidential candidate Bob Graham (D-FL), and Miss America 1995 Heather Whitestone McCallum. These stories can be found at: www.progressyoucansee.org.
AdvaMed member companies produce the medical devices, diagnostic products and health information systems that are transforming health care through earlier disease detection, less invasive procedures and more effective treatments. Its members produce nearly 90 percent of the health care technology purchased annually in the United States and more than 50 percent purchased annually around the world.
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. Abiomed currently manufactures and sells the AB5000(TM) Circulatory Support System and the BVS(R) 5000 Biventricular Support System for the temporary support of all patients with failing but potentially recoverable hearts. In Europe, Abiomed offers the IMPELLA(R) RECOVER(R) minimally invasive cardiovascular support systems under CE Mark approval. The IMPELLA(R) 2.5 is an investigational device limited by Federal Law solely to investigational use in the United States. Other IMPELLA devices are not yet available for sale in the United States. The Company's AbioCor(R) Implantable Replacement Heart was the subject of an initial clinical trial under an Investigational Device Exemption from the United States Food and Drug Administration. The AbioCor has not been approved for commercial distribution, and is not available for use or sale outside of the initial clinical trial. For additional information please visit: www.Abiomed.com.
This Release contains forward-looking statements, including statements regarding development of ABIOMED's existing and new products, the Company's progress toward commercial growth, and future opportunities. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.